-
Mashup Score: 107
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 107
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Source: jhoonline.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 86Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 16 day(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization To create an adaptation, translation, or derivative of the original work, for commercial e-pr ints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 66Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors - 2 month(s) ago
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-m
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 84Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 2 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors - 2 month(s) ago
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value. Second-generation TKIs may be the best frontline strategy when treatment-free remission is the goal. Recent studies have shown maintained efficacy and reduced toxicity when TKIs are used at reduced dosing. Reduced-dose schedules of second-generation TKIs (which are less toxic and induce faster deep molecular responses) may render generic second-generation TKIs a more attractive treatment option. Adjusting the dose of TKI in the presence of mild-to-m
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 83Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 2 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 2 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 147Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies - 3 month(s) ago
γδ T cells play an important role in disease control in acute myeloid leukemia (AML) and have become an emerging area of therapeutic interest. These cells represent a minor population of T lymphocytes with intrinsic abilities to recognize antigens in a major histocompatibility complex-independent manner and functionally straddle the innate and adaptive immunity interface. AML shows high expression of phosphoantigens and UL-16 binding proteins that activate the Vδ2 and Vδ1 subtypes of γδ T cells, respectively, leading to γδ T cell-mediated cytotoxicity. Insights from murine models and clinical data in humans show improved overall survival, leukemia-free survival, reduced risk of relapse, enhanced graft-versus-leukemia effect, and decreased graft-versus-host disease in patients with AML who have higher reconstitution of γδ T cells following allogeneic hematopoietic stem cell transplantation. Clinical trials leveraging γδ T cell biology have used unmodified and modified allogeneic cells a
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Gamma delta T cells are a novel immunotherapy for AML. Recent review from our group https://t.co/v8MgGKyeLv We have clinical trials w Aza Ven & gd2T cell activating ICT01 for Newly Dx AML, & allogeneic gd1T cells for R/R #AML https://t.co/66peT9TKvA https://t.co/LGMVN5oyyl #leusm https://t.co/GAnAXazoBU
-
Inotuzumab approved as monotherapy for R/R #ALL but new research is expanding its use into frontline, for MRD+, and in combo with blinatumomab. Best outcomes seen in combinations. @NicholasShortMD of @MDAndersonNews #Leukemia https://t.co/ikbkb9GdlZ #leusm https://t.co/NmEkqvVujj